No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
LH240517P175000
- 0.69
- 0.000.00%
15min DelayClose Apr 17 15:08 ET
0.00High0.00Low
0.00Open0.69Pre Close0 Volume32 Open Interest175.00Strike Price0.00Turnover1541.53%IV-15.11%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier-4DDays to Expiry0.69Time Value100Contract SizeAmericanOptions Type-0.0590Delta0.0045Gamma297.59Leverage Ratio-63.1599Theta0.0000Rho-17.55Eff Leverage0.0020Vega
Intraday
- 5D
- 1D
News
Labcorp Holdings (NYSE:LH) Is Due To Pay A Dividend Of $0.72
Express News | Laboratory Corporation of America Holdings Files for Debt Shelf; Size Not Disclosed- SEC Filing
Express News | NYSE Order Imbalance 73104.0 Shares on Buy Side
Insider Sale: EVP, Chief Legal Officer Van Der Vaart Sandra D Sells Shares of Laboratory Corp ...
Laboratory Corp of America(LH.US) Officer Sells US$421.66K in Common Stock
$Laboratory Corp of America(LH.US)$ Officer van der Vaart Sandra D sold 2,000 shares of common stock on May 14, 2024 at an average price of $210.8276 for a total value of $421.66K.Source: Announcement
Laboratory Corp Of America Holdings Insider Sold Shares Worth $421,655, According to a Recent SEC Filing
Sandra D Van Der Vaart, EVP, Chief Legal Officer, on May 14, 2024, sold 2,000 shares in Laboratory Corp Of America Holdings (LH) for $421,655. Following the Form 4 filing with the SEC, Sandra D Van De
Comments
The company's stock seems overpriced compared to its peers, suggesting limited potential for further growth. Its low beta indicates it may not align with industry levels soon.
Insider selling shares below current price suggests contentment with lower valuation. Lack of insider buying and low insider ownership make the company a cautious investment choice.
Investors' optimism about Laboratory Corporation's performance could lead to inflated stock prices. The high share price puts existing and new shareholders at potential risk, possibly paying an unnecessary premium.
Labcorp's acquisition set to fortify its Massachusetts presence and push its goal of broadening cost-effective lab testing. The partnership with Baystate Health aims at promoting efficient, advanced healthcare services and improving patient and provider experience.
Read more